DA32 Life Science Tech Acquisition Corp. announced the pricing of its $200 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol “DALS” Wednesday, July 28.

The new SPAC, sponsored by affiliates of Deerfield Management Company, L.P. (“Deerfield”), ARCH Venture Partners (“ARCH”) and Section 32, aims to combine with a target that addresses unmet research, clinical or commercial needs in a large and growing addressable market. DA32 Life Science Tech is led by CEO Steve Kafka and CFO and Secretary Christopher Wolfe.

Total SPAC deal count for 2021 year-to-date is now 383. This offering is expected to close on Friday, July 30.

J.P. Morgan Securities LLC and Cowen and Company, LLC are serving as joint bookrunning managers of the offering. White & Case LLP is serving as Issuer’s Counsel with Kirkland & Ellis LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.